Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis
Open Access
- 16 November 2023
- journal article
- research article
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (4) , 676-687
Abstract
This study undertakes a comprehensive comparison of five different interventions for the treatment of type-1 retinopathy of prematurity (ROP) and aggressive posterior ROP (APROP), offering insights into their relative efficacies and contributing to better clinical decision making. The aim of this study was to compare the efficacy of intravitreal aflibercept (IVA), intravitreal bevacizumab (IVB), intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), and laser therapy in treating these conditions. We conducted a search for relevant randomized controlled trials (RCTs) in databases, namely, PubMed, Embase, Cochrane Library, Web of Science, and Ovid, focusing on these five treatment modalities for ROP. The quality of the included studies was evaluated using the Cochrane Risk of Bias Assessment Tool, and data analysis was performed using STATA software. The results from our network meta-analysis (NMA) indicated that IVA significantly prolonged the interval between initial treatment and relapse in patients, with a surface under the cumulative ranking curve (SUCRA) value of 99.1%. Additionally, patients in the IVB group had a significantly higher spherical equivalent refraction (SER) after surgery, with a SUCRA value of 84.4%. Furthermore, IVR was the most effective in reducing the duration of peripheral retinal vascularization, with a SUCRA value of 95.6%. However, no statistically significant differences were found in relapse rates among the five treatment options. Our analysis concludes that intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drug monotherapy generally offer better outcomes than laser treatment for ROP. Nonetheless, additional RCTs are necessary to further evaluate the safety of anti-VEGF agents.Keywords
This publication has 48 references indexed in Scilit:
- Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injectionGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
- Comparative effectiveness of breathing exercises in patients with chronic obstructive pulmonary diseaseComplementary Therapies in Clinical Practice, 2020
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of InterventionsCochrane Database of Systematic Reviews, 2019
- Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurityGraefe's Archive for Clinical and Experimental Ophthalmology, 2018
- Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser TreatmentAmerican Journal of Ophthalmology, 2018
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse EventsJAMA, 2016
- Treatment of type 1 retinopathy of prematurity with bevacizumab versus laserJournal of American Association for Pediatric Ophthalmology and Strabismus, 2015
- Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser TreatmentJAMA Ophthalmology, 2014
- Intravitreal Bevacizumab for Retinopathy of Prematurity: Refractive Error ResultsAmerican Journal of Ophthalmology, 2013
- Multivariate meta‐analysis: Potential and promiseStatistics in Medicine, 2011